Molecular mechanisms regulating vascular tone by peroxisome proliferator activated receptor gamma

Current Opinion in Nephrology and Hypertension

Volumn 24, Issue 2, 2015, Pages 123-130

  Ketsawatsomkron, Pimonrat ^a   Sigmund, Curt D ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Endothelial cells; Peroxisome proliferator activated receptor g; Smooth muscle cells; Vasculature; Vessel tone

Indexed keywords

ANGIOTENSIN II; CATALASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RENIN; SUPEROXIDE DISMUTASE;

ARTICLE; BLOOD VESSEL TONE; GENE TARGETING; HUMAN; INFLAMMATION; METABOLISM; MOLECULAR MECHANICS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN METABOLISM; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SMOOTH MUSCLE FIBER; TRANSCRIPTION INITIATION; VASODILATATION; ANIMAL; GENETICS; PHYSIOLOGY; SMOOTH MUSCLE CELL; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN II; ANIMALS; HUMANS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NADPH OXIDASE; PPAR GAMMA; RENIN-ANGIOTENSIN SYSTEM;

EID: 84922671172     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000103     Document Type: Article

References (50)

1. Lefterova MI, Haakonsson AK, Lazar MA, Mandrup S. PPARγ and the global map of adipogenesis and beyond. Trends Endocrinol Metab 2014; 25:293-302.
2. Lefterova MI, Steger DJ, Zhuo D, et al. Cell-specific determinants of peroxisome proliferator-activated receptor gamma function in adipocytes and macrophages. Mol Cell Biol 2010; 30:2078-2089.
3. Ahmadian M, Suh JM, Hah N, et al. PPARg signaling and metabolism: the good, the bad and the future. Nat Med 2013; 19:557-566.
4. Giles TD, Sander GE. Effects of thiazolidinediones on blood pressure. Curr Hypertens Rep 2007; 9:332-337.
5. Sigmund CD. A clinical link between peroxisome proliferator-activated receptor gamma and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2013; 33:676-678.
6. Eldor R, DeFronzo RA, Abdul-Ghani M. In vivo actions of peroxisome pro-liferator- activated receptors: glycemic control, insulin sensitivity, and insulin secretion. Diabetes Care 2013; 36 (Suppl 2):S162-S174. This study summarizes evidence on the pleiotropic effects of TZD on glycemic control and insulin sensitivity and highlights the long-lasting glycemic control of TZD over other antidiabetes drugs.
7. Dutchak PA, Katafuchi T, Bookout AL, et al. Fibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinediones. Cell 2012; 148:556-567.
8. Sun K, Scherer PE. The PPARg-FGF1 axis: an unexpected mediator of adipose tissue homeostasis. Cell Res 2012; 22:1416-1418.
9. Jonker JW, Suh JM, Atkins AR, et al. A PPARγ-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature 2012; 485:391-394.
10. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457-2471.
11. Press announcements: FDA requires removal of certain restrictions on the diabetes drug Avandia [press release]. 2013. http://www.fda.gov/News Events/Newsroom/PressAnnouncements/ucm376516.htm FDA removed the restriction for rosiglitazone use in patients with type 2 diabetes after the re-adjudication of results of the RECORD trial showed no significant increased risk in heart attack or death in patients treated with rosiglitazone.
12. Soccio RE, Chen ER, Lazar MA. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab 2014; 20:573-591. Risk-benefit analysis of TZD based on clinical data, basic sciences, novel mechanisms regulating PPARγ activity and potential new therapeutics targeting PPARg with less side effects.
13. Auclair M, Vigouroux C, Boccara F, et al. Peroxisome proliferator-activated receptor-gamma mutations responsible for lipodystrophy with severe hypertension activate the cellular renin-angiotensin system. Arterioscler Thromb Vasc Biol 2013; 33:829-838. This study identified two new PPARγ mutations in patients with lipodystrophy, insulin resistance and severe hypertension associated with a cellular increase in the RAS, oxidative stress and inflammation.
14. Agostini M, Schoenmakers E, Mitchell C, et al. Non-DNA binding, dominantnegative, human PPARgamma mutations cause lipodystrophic insulin resistance. Cell Metab 2006; 4:303-311.
15. Barroso I, Gurnell M, Crowley VE, et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999; 402:880-883.
16. Beyer AM, Baumbach GL, Halabi CM, et al. Interference with PPARgamma signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling. Hypertension 2008; 51:867-871.
17. Chang L, Villacorta L, Zhang J, et al. Vascular smooth muscle cell-selective peroxisome proliferator-activated receptor-gamma deletion leads to hypotension. Circulation 2009; 119:2161-2169.
18. Kanda T, Brown JD, Orasanu G, et al. PPARgamma in the endothelium regulates metabolic responses to high-fat diet in mice. J Clin Invest 2009; 119:110-124.
19. Halabi CM, Beyer AM, de Lange WJ, et al. Interference with PPAR gamma function in smooth muscle causes vascular dysfunction and hypertension. Cell Metab 2008; 7:215-226.
20. Beyer AM, de Lange WJ, Halabi CM, et al. Endothelium-specific interference with peroxisome proliferator activated receptor gamma causes cerebral vascular dysfunction in response to a high-fat diet. Circ Res 2008; 103:654-661.
21. Marchesi C, Rehman A, Rautureau Y, et al. Protective role of vascular smooth muscle cell PPARγ in angiotensin II-induced vascular disease. Cardiovasc Res 2013; 97:562-570. Despite unaltered systemic blood pressure, loss of smooth muscle PPARg exacerbated angiotensin II induced small mesenteric arteries remodeling, endothelial dysfunction and vascular inflammation.
22. Polikandriotis JA, Mazzella LJ, Rupnow HL, Hart CM. Peroxisome proliferatoractivated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gammadependent mechanisms. Arterioscler Thromb Vasc Biol 2005; 25:1810-1816.
23. Hwang J, Kleinhenz DJ, Lassegue B, et al. Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production. Am J Physiol Cell Physiol 2005; 288:C899-C905.
24. Tian J, Wong WT, Tian XY, et al. Rosiglitazone attenuates endothelin-1- induced vasoconstriction by upregulating endothelial expression of endothelin B receptor. Hypertension 2010; 56:129-135.
25. Nicol CJ, Adachi M, Akiyama TE, Gonzalez FJ. PPARgamma in endothelial cells influences high fat diet-induced hypertension. Am J Hypertens 2005; 18 (4 Pt 1):549-556.
26. Wang N, Symons JD, Zhang H, et al. Distinct functions of vascular endothelial and smooth muscle PPARgamma in regulation of blood pressure and vascular tone. Toxicol Pathol 2009; 37:21-27.
27. Kleinhenz JM, Kleinhenz DJ, You S, et al. Disruption of endothelial peroxisome proliferator-activated receptor-gamma reduces vascular nitric oxide production. Am J Physiol Heart Circ Physiol 2009; 297:H1647-H1654.
28. Wang N, Yang G, Jia Z, et al. Vascular PPARgamma controls circadian variation in blood pressure and heart rate through Bmal1. Cell Metab 2008; 8:482-491.
29. Wan Y, Saghatelian A, Chong LW, et al. Maternal PPAR gamma protects nursing neonates by suppressing the production of inflammatory milk. Genes Dev 2007; 21:1895-1908.
30. Wan Y, Chong LW, Evans RM. PPAR-gamma regulates osteoclastogenesis in mice. Nat Med 2007; 13:1496-1503.
31. Yin KJ, Fan Y, Hamblin M, et al. KLF11 mediates PPARgamma cerebrovascular protection in ischaemic stroke. Brain 2013; 136 (Pt 4):1274- 1287. Selective disruption of PPARγin vascular endothelial cells led to increased cerebrovascular permeability and brain damage during ischemia. KLF11 was identified as a new PPARγcoregulator in endothelial cells required for TZD mediated cerebrovascular protection during ischemic stroke.
32. Pelham CJ, Keen HL, Lentz SR, Sigmund CD. Dominant negative PPARγ promotes atherosclerosis, vascular dysfunction, and hypertension through distinct effects in endothelium and vascular muscle. Am J Physiol Regul Integr Comp Physiol 2013; 304:R690-R701. Endothelial dysfunction and hypertension were unmasked when loss of apolipoprotein E was compounded with the presence of mutant PPARg in endothelial cells.
33. Girnun GD, Domann FE, Moore SA, Robbins ME. Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter. Mol Endocrinol 2002; 16:2793-2801.
34. Yoo HY, Chang MS, Rho HM. Induction of the rat Cu/Zn superoxide dismutase gene through the peroxisome proliferator-responsive element by arachidonic acid. Gene 1999; 234:87-91.
35. Mehrotra D, Wu J, Papangeli I, Chun HJ. Endothelium as a gatekeeper of fatty acid transport. Trends Endocrinol Metab 2014; 25:99-106.
36. Goto K, Iso T, Hanaoka H, et al. Peroxisome proliferator-activated receptorgamma in capillary endothelia promotes fatty acid uptake by heart during longterm fasting. J Am Heart Assoc 2013; 2:e004861. Activation of PPARγ facilitated fatty acid uptake in microvessel endothelial cells through induction of classic target genes, aP2 and CD36.
37. Borges GR, Morgan DA, Ketsawatsomkron P, et al. Interference with peroxisome proliferator-activated receptor-gamma in vascular smooth muscle causes baroreflex impairment and autonomic dysfunction. Hypertension 2014; 64:590-596. Altered carotid arterial remodeling and neurovascular signaling caused by compromised smooth muscle PPARγ activity links vascular dysfunction to impaired baroreflex.
38. Pelham CJ, Ketsawatsomkron P, Groh S, et al. Cullin-3 regulates vascular smooth muscle function and arterial blood pressure via PPARg and RhoA/ Rho-kinase. Cell Metab 2012; 16:462-472.
39. De Silva TM, Modrick ML, Ketsawatsomkron P, et al. Role of peroxisome proliferator-activated receptor-gamma in vascular muscle in the cerebral circulation. Hypertension 2014; 64:1088-1093. This study emphasizes the critical role of PPARγ in brain circulation.
40. Ketsawatsomkron P, Lorca RA, Keen HL, et al. PPAR g regulates resistance vessel tone through a mechanism involving RGS5-mediated control of protein kinase C and BKCa channel activity. Circ Res 2012; 111:1446-1458.
41. Carrillo-Sepulveda MA, Keen HL, Davis DR, et al. Role of vascular smooth muscle PPARγ in regulating AT1 receptor signaling and angiotensin IIdependent hypertension. PLoS One 2014; 9:e103786. Expression of PPARγ mutant in smooth muscle cells resulted in increased angiotensin-II signaling.
42. Holobotovskyy V, Manzur M, Tare M, et al. Regulator of G-protein signaling 5 controls blood pressure homeostasis and vessel wall remodeling. Circ Res 2013; 112:781-791. RGS5 plays a critical role in blood pressure regulation and vascular homeostasis through angiotensin II signaling with PKC, MAPK and Rho kinase as downstream effectors.
43. Huang Y, Di Lorenzo A, Jiang W, et al. Hypoxia-inducible factor-1alpha in vascular smooth muscle regulates blood pressure homeostasis through a peroxisome proliferator-activated receptor-gamma-angiotensin II receptor type 1 axis. Hypertension 2013; 62:634-640. HIF1a deficiency increased AT1 receptor in smooth muscle and that correlated with reduced PPARγ expression.
44. Schleifenbaum J, Kassmann M, Szijarto IA, et al. Stretch-activation of angiotensin II type 1a receptors contributes to the myogenic response of mouse mesenteric and renal arteries. Circ Res 2014; 115:263-272. This study provides evidence that identified AT1R as a mechano-sensor during myogenic constriction.
45. Chang L, Villacorta L, Li R, et al. Loss of perivascular adipose tissue on peroxisome proliferator-activated receptor-gamma deletion in smooth muscle cells impairs intravascular thermoregulation and enhances atherosclerosis. Circulation 2012; 126:1067-1078.
46. Hou Y, Moreau F, Chadee K. PPARgamma is an E3 ligase that induces the degradation of NFkappaB/p65. Nat Commun 2012; 3: 1300.
47. Pascual G, Fong AL, Ogawa S, et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005; 437:759-763.
48. Glass CK, Saijo K. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol 2010; 10:365-376.
49. Choi JH, Banks AS, Estall JL, et al. Antidiabetic drugs inhibit obesitylinked phosphorylation of PPARgamma by Cdk5. Nature 2010; 466:451-456.
50. Qiang L, Wang L, Kon N, et al. Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Pparg. Cell 2012; 150:620-632.